Angela Maral, APRN
Acute Care · Omaha, NENPI 1104506872
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AstraZeneca at 40.5% of the total.
Across 19 payments — averaging $23.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$177
- Otsuka America Pharmaceutical, Inc.$66
- Philips North America LLC$61
- Collegium Pharmaceutical, Inc.$60
- Lundbeck LLC$25
- Johnson & Johnson$18
- plus $31 from 2 others
What the payments were for
- Food & beverage$438100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 6 | $177 |
| Otsuka America Pharmaceutical, Inc. | 3 | $66 |
| Philips North America LLC | 3 | $61 |
| Collegium Pharmaceutical, Inc. | 3 | $60 |
| Lundbeck LLC | 1 | $25 |
| Johnson & Johnson | 1 | $18 |
| Novo Nordisk | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
How this compares
$438 in reported general payments places this provider in the 55th percentile of 103 acute care providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 27 | $799 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $386 |
| Fluticasone Propionate | 22 | $317 |
| Oxycodone Hcl | 13 | $288 |
| Gabapentin | 19 | $261 |
| Metoprolol Succinate | 17 | $226 |
| Levothyroxine Sodium | 25 | $217 |
| Omeprazole | 14 | $188 |
| Atorvastatin Calcium | 23 | $163 |
| Tamsulosin Hcl | 13 | $151 |
| Metformin Hcl | 29 | $144 |
| Lorazepam | 26 | $127 |
| Amlodipine Besylate | 28 | $112 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $111 |
| Tramadol Hcl | 17 | $110 |
Paid to pharmacies, not to this prescriber.
Other acute care in Omaha
- Jennifer BecherOmaha$7K
- Mary LauerOmaha$7K
- Rachel RagerOmaha$6K
- Brittany KellyOmaha$4K
- Angela ClabornOmaha$3K
- Amy SwerczekOmaha$2K
- Stephanie ChristensenOmaha$2K
- Angela SivertsonOmaha$2K
- Cassandra KaczmarekOmaha$2K
- Elisabeth ElganOmaha$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.